In this multicentre real-world cohort of patients with GCA, including those with relapsing disease and previous biologic exposure, secukinumab was associated with high observed remission rates, progressive GC dose reduction and increasing GC-free remission.
Abstract
Objective
The objective of this study was to evaluate the real-world effectiveness and safety of secukinumab in giant cell arteritis (GCA) patients.
Methods
This multicentre retrospective study included patients with GCA who received secukinumab at 14 Italian centres with at least 6 months of follow-up. Outcomes included clinical, complete and glucocorticoid (GC)-free remission, GC dose reduction, drug retention rate and adverse events.
Results
Thirty-six patients were included (66.7% women); median age at secukinumab initiation was 74 (IQR 70-80) years. Overall, 32/36 patients (88.9%) had previously relapsed and 26/36 (72.2%) had received tocilizumab. Clinical remission was observed in 85.2%, 80.6% and 83.3% at 3, 6 and 12 months, respectively. Complete remission occurred in 55.6%, 52.8% and 63.3%, while GC-free remission increased progressively, reaching 14.8%, 27.8% and 40.0% at 3, 6, and 12 months, respectively (p = 0.012). Median daily GC dose decreased from 8.7 [4.0-21.2] mg at baseline to 0 [0-5.0] mg at 12 months (p < 0.001); GCs were discontinued in 12/28 patients (42.9%). The 12-month retention rate was 77.0%. Adverse events occurred in 20/36 patients (55.6%); infections occurred in 18/36 (50.0%) patients, accounting for 21 infectious episodes.
Conclusion
In this multicentre real-world cohort of patients with GCA, including those with relapsing disease and previous biologic exposure, secukinumab was associated with high observed remission rates, progressive GC dose reduction and increasing GC-free remission. Although the phase III GCAptAIN trial did not meet its primary endpoint, these findings suggest that IL-17A inhibition may warrant further evaluation in GCA patients.
Background: Anti-CD20 therapies are widely used in multiple sclerosis (MS), and real-world data may complement findings from clinical trials. Objective: The objective is to evaluate the effectiveness and safety of ofatumumab and ocrelizumab in patients with MS in a real-world setting. Methods: This was a single-center,...
Carolina Mibielli de Souza, Samara Abdo El Hakim Kadri, C. Disserol et al.· ANPAbstract_CBN26· 0 citations
Evaluating the long-term drug survival of adalimumab in a large cohort of patients with Behçet's syndrome found a good retention rate at month 6, followed by a gradual decline in drug retention over time.
Ozge Sonmez, S. N. Esatoğlu, D. Uçar et al.· Rheumatology· 0 citations
Real-world evidence on ocrelizumab in multiple sclerosis (MS) from the Middle East and North Africa (MENA) is limited. We extended our original Q-OCRE cohort (n = 60) to evaluate effectiveness and safety in an ethnically diverse Gulf population. In a single-center retrospective cohort of all patients starting ocrelizum...
Khaled Zammar, Majd A. Abualrob, Randa Yasin et al.· Multiple Sclerosis and Relat...· 0 citations
OBJECTIVES
To evaluate the real-world effectiveness and safety of tocilizumab (TCZ) in glucocorticoid (GC)-resistant adult-onset Still's disease (AOSD) and explore predictors of clinical response.
METHODS
This prospective, single-centre cohort study enrolled consecutive eligible patients with GC-resistant AOSD who in...
Dou-Dou Ma, Hai-Hong Yao, Xia Zhang et al.· Clinical and Experimental Rh...· 0 citations
BACKGROUND
Many patients with Crohn’s disease (CD) remain uncontrolled despite multiple biologic therapies. Risankizumab, a selective interleukin-23p19 inhibitor, has shown efficacy in clinical trials, but real-world data in multirefractory CD are still scarce.
AIM
To evaluate the 12-month effectiveness and safety o...
A. Caballero-Mateos, T. Valdés-Delgado, R. Olmedo Martín et al.· World Journal of Gastroenter...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.